Anove LogoAnove LogoExplAIn
MapsAI frontrunners
Back to Directory

Aiosyn AI-Powered Pathology Tool

by Aiosyn

AI Application
Low Confidence

Aiosyn provides AI-powered precision pathology software for clinical diagnostics and medical research. Its solutions include computational pathology tools for analyzing renal biopsies, detecting mitoses, and identifying pathology-based biomarkers. Aiosyn's platform integrates into standard pathology workflows, offering objective quantification of stained tissue, improving efficiency, and supporting drug development for biopharma and research organizations.

Visit Website

Transparency Score

Weighted across four pillars · updated October 20, 2026

Overall grade
35% weighted
ABCDF
Model
—
Not yet assessed
Infrastructure
—
Not yet assessed

Capabilities

AI Powered Pathology
Renal Biopsy Analysis
Mitosis Detection
Biomarker Discovery
Clinical Diagnostic Support
Preclinical Studies
Drug Development Support
Computational Pathology
Digital Pathology Workflow
Tissue Quantification

Vendor Information

Complete information about the vendor/provider of this AI application

AiosynView all products →
Aiosyn B.V.(Trading as: Aiosyn)
Contact Information
www.aiosyn.com/
contact@aiosyn.com
Registered Address
Toernooiveld 300, Nijmegen, Gelderland, 6525 EC, NL

EU AI Act Provider Information

Verification Status:
Verified
(Last verified: October 20, 2026)
Aiosyn B.V.(Trading as: Aiosyn)
Toernooiveld 300, Nijmegen, Gelderland, 6525 EC, NL
contact@aiosyn.com
Aiosyn says AiosynQC is not a medical device under the IVDR or UK MDR 2002, is not intended as an accessory to any AI or other medical device, and is research use only in the United States and other jurisdictions; it says Aiosyn Mitosis Breast is for research use only and that, unless otherwise mentioned, its applications are research use only or not medical devices (https://www.aiosyn.com/automated-quality-control/, https://www.aiosyn.com/mitotic-figure-counting/, https://www.aiosyn.com/clinical/, read 2026-10-20). In January 2025 Aiosyn announced IVDR CE marking for Mitosis Breast; class and notified body were not published and EUDAMED lists no certificate.
Compliance & Risk

Get insights into risk by running assessments on this AI application.

Work at Aiosyn? Claim this listing to correct or complete the data.

Added: September 10, 2026
Updated: October 20, 2026

Ready to manage AI applications?

Track, assess, and govern your AI applications with Anove.

Anove LogoAnove LogoAnove International B.V.

Helping organizations discover and manage AI applications responsibly. Your trusted source for AI governance and compliance.

Quick Links

  • Browse Directory
  • FAQ
  • AI maps by industry
  • Sign In

Resources

  • Documentation
  • Status
  • Anove.ai

Terms

  • Privacy Policy
  • Terms & Conditions
  • Responsible Disclosure
  • AI Legal Notice
  • Security Policy

© 2026 Anove International B.V. All rights reserved.